Status:
UNKNOWN
Jinghua Weikang Capsule Containing Quadruple Therapy for IgAN With Helicobacter Pylori Infection
Lead Sponsor:
Peking University First Hospital
Conditions:
Helicobacter Pylori Infection
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
This study is to evaluate the efficacy and safety of the Jinghua Weikang Capsule (a Chinese patent medicine for peptic ulcer and gastritis) containing quadruple therapy (Jinghua Weikang Caplsule plus ...
Eligibility Criteria
Inclusion
- IgA nephropathy diagnosed by renal biopsy;
- Current Helicobacter pylori infection;
- Age 18-65.
Exclusion
- ①eGFR\<90ml/（min·1.73m2）-
- History of Helicobacter pylori treatment
- Present taking hormones or immunosuppressants
- Malignant tumor and high-grade intraepithelial neoplasia and severe dysplasia of gastric mucosa
- Allergy history to medicines used in the study
- History of gastric surgery
- Uncontrolled chronic diseases such as diabetes, cardiovascular and cerebrovascular diseases, respiratory diseases, mental disorders and other researchers are considered to affect treatment and assessment
- Combined with other primary or secondary nephropathy except for IgAN
- Combined with acute renal injury
- Female patients with pregnancy, lactation and planned pregnancy.
Key Trial Info
Start Date :
June 20 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT05320133
Start Date
June 20 2022
End Date
December 31 2024
Last Update
October 18 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University First Hospital
Beijing, Beijing Municipality, China, 100034